The use of cancer immunology drugs as mono- and combined therapy for locally advanced and metastatic bladder cancer (a review of clinical trials)

Kotenko D.V.

doi:https://doi.org/10.17116/onkolog20198061466

Kotenko D.V.

A.I. Evdokimov Moscow State Medical and Dental University, Moscow, Russia

The use of cancer immunology drugs as mono- and combined therapy for locally advanced and metastatic bladder cancer (a review of clinical trials)

Authors:

Kotenko D.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2019;8(6): 466‑470

DOI: 10.17116/onkolog20198061466

Read: 4621 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kotenko DV. The use of cancer immunology drugs as mono- and combined therapy for locally advanced and metastatic bladder cancer (a review of clinical trials). P.A. Herzen Journal of Oncology. 2019;8(6):466‑470. (In Russ.)
https://doi.org/10.17116/onkolog20198061466

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Efficacy of chemoimmunotargeted therapy in patients with advanced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Oncology. 2025;(3):63-70

The effectiveness of combined chemotherapy and immunotherapy, and the search for personalized approaches to treating advanced non-small cell lung cancer. P.A. Herzen Journal of Oncology. 2025;(4):37-45

Results of the use of immune checkpoint inhibitors in the treatment of small cell lung cancer in real-life clinical practice: results of a single-center observational study. P.A. Herzen Journal of Oncology. 2025;(4):46-53

Possibilities of drug treatment for pseudomyxoma peritonei of appendiceal origin. P.A. Herzen Journal of Oncology. 2025;(6):59-64

Prognostically unfavorable types of breast cancer. P.A. Herzen Journal of Oncology. 2025;(6):78-82

Application of T-cells with chimeric antigen receptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medicine. 2025;(7):106-110

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

The impact of combined immunotherapy on the cellular composition of the tumor microenvironment in patients with gastric carcinoma. Russian Journal of Archive of Pathology. 2025;(4):24-30

Predictive immunotherapeutic markers of adenocarcinomas and adenosquamous carcinoma of the cervix. Russian Journal of Archive of Pathology. 2025;(5):74-79

Clinical efficacy of dupilumab monoclonal antibody in the treatment of recurrent severe chronic rhinosinusitis with nasal polyps without bronchial asthma. Russian Rhinology. 2025;(4):32-37

Abstract:

Until recently, only a few types of second-line chemotherapy have been available for the treatment of patients with platinum-resistant bladder cancer, which had led to an urgent need to change the approach to medical care to this category of patients. The receptors of programmed cell death 1 (PD-1) and its ligand (PD-L1) have become a focus of cancer research as targets for cancer immunotherapy, culminating in the development of monoclonal antibodies and immune checkpoint inhibitors. The paper reviews the main clinical trials of the efficiency of immunotherapy.

Keywords:

immunotherapy

monoclonal antibodies

bladder cancer

atezolizumab

pembrolizumab

nivolumab

Authors:

Kotenko D.V.

A.I. Evdokimov Moscow State Medical and Dental University, Moscow, Russia

Close metadata

References:

Kaprin AD, Starinskii VV, Petrova GV, eds. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2018. Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii, 2019. (In Russ.)
Powles T, Smith K, Stenzl A, Bedke J. Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol. 2017;72(4):477-481. https://doi.org/10.1016/j.eururo.2017.03.047
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76. https://doi.org/10.1016/S0140-6736(16)32455-2
Vander Velde N, Guerin A, Ionescu-Ittu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thåström A, Liu S, Shi L, Leppert JT. Comparative effectiveness of non-cisplatin first-line therapies for metastatic urothelial carcinoma: Phase 2 IMvigor210 study versus US patients treated in the veterans health administration. Eur Urol. 2019;2(1):12-20. https://doi.org/10.1016/j.euo.2018.07.003
Sternberg CN, Loriot Y, James N, Choy E., Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, et al. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol. 2019;76(1):73-81. https://doi.org/10.1016/j.eururo.2019.03.015
Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748-757. https://doi.org/10.1016/S0140-6736(17)33297-X
Powles T, Loriot Y, Durán I, et al. IMvigor211: a phase III randomized study examining atezolizumab vs. chemotherapy for platinum-treated advanced urothelial carcinoma. In: Presented at: 2^nd Special Conference EACR AACR SIC. Florence (Italy) 2017 June 24-27.
Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, et al. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: Check Mate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol. 2019;24(9):1089-1098. https://doi.org/10.1007/s10147-019-01450-w
Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol. 2019;30(6):970-976. https://doi.org/10.1093/annonc/mdz127
Darr C, Hadaschik BA, Tschirdewahn S. Systemic treatment of metastatic tumors of the upper urinary tract. Urologe A. 2019;58(1):30-33. https://doi.org/10.1007/s00120-018-0835-8
Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: metaanalysis. BMJ. 2018;362:k3529. https://doi.org/10.1136/bmj.k3529